Posts

Posted on

BioRestorative Confirms No Material Impact from Reciprocal Tariffs; All BRTX-100 Production & Manufacturing Performed in the United States

MELVILLE, N.Y., April 10, 2025 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to confirm that it currently faces no material exposure to newly imposed U.S. tariffs.

BRTX-100, a novel cell-based therapeutic engineered to target areas of the body that have little blood flow, is BioRestorative’s lead clinical candidate. The safety and efficacy of BRTX-100 in treating chronic lumbar disc disease (“cLDD”) is being evaluated in a Phase 2, prospective, randomized, double-blinded and controlled study. The U.S. Food and Drug Administration (“FDA”) recently granted Fast Track designation to the BRTX-100 program for the treatment of cLDD, reflecting the positive preliminary Phase 2 safety and efficacy data reported to date. Also in February, the FDA cleared the Company’s Investigational New Drug (“IND”) application for BRTX-100 for the treatment of chronic cervical discogenic pain (cCDP), expanding BioRestorative’s advanced clinical pipeline for BRTX-100 to include the treatment of both chronic lower back and neck pain.

“Our ‘made-in-America’ production and manufacturing strategy, combined with our use of domestic inputs, enables us to effectively manage costs amid global supply chain shifts,” said Lance Alstodt, BioRestorative’s Chief Executive Officer. “We ended 2024 in a very strong financial position with cash, cash equivalents, marketable securities of over $10 million. We plan on continuing to efficiently manage our cash reserves while executing upon all of our strategic goals.”

About BioRestorative Therapies, Inc.

BioRestorative (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. As described below, our two core clinical development programs relate to the treatment of disc/spine disease and metabolic disorders, and we have also recently begun offering BioCosmeceutical products:

• Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have commenced a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. We have also obtained U.S. Food and Drug Administration (“FDA”) Investigational New Drug (“IND”) clearance to evaluate BRTX-100 in the treatment of chronic cervical discogenic pain.

• Metabolic Program (ThermoStem®): We are developing cell-based therapy candidates to target obesity and metabolic disorders using brown adipose (fat) derived stem cells (“BADSC”) to generate brown adipose tissue (“BAT”), as well as exosomes secreted by BADSC. BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes. BADSC secreted exosomes may also impact weight loss.

• BioCosmeceuticals: We operate a commercial BioCosmeceutical platform. Our current commercial product, formulated and manufactured using our cGMP ISO-7 certified clean room, is a cell-based secretome containing exosomes, proteins and growth factors. This proprietary biologic serum has been specifically engineered by us to reduce the appearance of fine lines and wrinkles and bring forth other areas of cosmetic effectiveness. Moving forward, we also intend to explore the potential of expanding our commercial offering to include a broader family of cell-based biologic aesthetic products and therapeutics IND-enabling studies, with the aim of pioneering FDA approvals in the emerging BioCosmeceuticals space.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company’s latest Form 10-K, as amended, filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

CONTACT:

Stephen Kilmer
Investor Relations
Direct: (646) 274-3580
Email: [email protected]



Posted on

Despite Volatility in the Markets Global Drone Market Is Expected to Achieve Remarkable Growth as Usage Skyrockets

PALM BEACH, Fla., April 10, 2025 (GLOBE NEWSWIRE) — FN Media Group News Commentary – Manufactures are projected to see increased manufacturing and sales in the global drone market for the coming several years. Rapid advancements in drone technology are significantly contributing to the drones market growth. Innovations such as artificial intelligence (AI), machine learning (ML), and improved sensor technology have enhanced the capabilities of drones, enabling them to perform more complex tasks with greater precision and efficiency. The integration of AI and ML, for instance, allows drones to analyze data in real-time, optimize flight paths, and make autonomous decisions. Furthermore, advancements in battery technology and propulsion systems have improved the endurance and range of drones, allowing them to operate for longer periods and cover greater distances. With the development of more efficient and environmentally friendly drones, market players are focusing on delivering drones with enhanced payload capacities, durability, and flight times. A report from Research And Markets said that the global drones market size aided by the increasing adoption of drones across various sectors, including agriculture, defense, logistics, and entertainment, the market is projected to continue to grow at a CAGR of 22.4% through 2032 to reach a value of USD 244.95 billion by 2032.” Active Companies in the drone industry today include ZenaTech, Inc. (NASDAQ: ZENA), Safe Pro Group Inc. (NASDAQ: SPAI), Ondas Holdings Inc. (NASDAQ: ONDS), AgEagle Aerial Systems Inc. (NYSE: UAVS), NVIDIA Corporation (NASDAQ: NVDA).

The report said: “As per the global drones market analysis, the increasing interest in urban air mobility (UAM) and the potential for passenger drones and air taxis represent a transformative opportunity for the transportation sector. Several companies and startups are already developing drone-based urban transport solutions, which could redefine urban mobility and create new market segments in the coming years. In conclusion, the global drones market value is set to increase in the coming years, driven by advancements in technology, expanding applications, and increasing demand across a wide range of sectors. Despite facing regulatory challenges and high costs, the market is set to witness robust expansion as drones become an integral part of modern industries, from agriculture to logistics to entertainment. By 2032, the market is expected to achieve remarkable growth, providing numerous opportunities for innovation, investment, and development across the globe.”

ZenaTech (NASDAQ:ZENA) Closes Miller Land Surveying Corporation, a Third Southeast Acquisition and a Fourth Nationally for the Drone as Service (DaaS) Rollout – ZenaTech, Inc. (FSE: 49Q) (BMV: ZENA) (“ZenaTech”), a technology company specializing in AI (Artificial Intelligence) drone, Drone-as-a-Service (DaaS), enterprise SaaS and Quantum Computing solutions, announces the closing of its acquisition of Miller Land Surveying Corporation (“Miller”) of Lake Worth, Florida, a land survey and mapping company with a 40 year history and deep portfolio of business customers in the Palm Beach County area of South Florida.

This is ZenaTech’s third acquisition in the Southeast region as part of a larger national roll-up strategy to disrupt the land survey industry by accelerating the use of drones for their speed and accuracy benefits. The acquisition also furthers the Company’s national Drone as a Service, or DaaS, business rollout as the fourth US acquisition.

“Miller Land Surveying brings a wealth of experience and customer relationships as a second-generation company known across Palm Beach County for quality land surveys and mapping. Their pioneering team is well suited to helping us bring drone innovation to premium residential and business land surveys. This acquisition is another step towards our vision to create a national DaaS business, bringing AI drone efficiencies and precision to a variety of legacy business verticals and manual tasks,” said CEO Shaun Passley, Ph.D.

ZenaTech’s DaaS business will incorporate the ZenaDrone 1000 and the IQ series of multifunction autonomous drones to provide a variety of service solutions from land surveys to power line inspections or power washing, made accessible and cost effective through an Uber-like business model on a regular subscription or pay-per-use basis. Customers can conveniently access drones for eliminating manual or time-consuming tasks achieving superior results, such as for surveying, inspections, security and law enforcement, or precision farming applications, without having to buy, operate, or maintain the drones themselves.

The DaaS business model offers customers such as government agencies, real estate developers, construction firms, farmers or energy companies reduced upfront costs as there is no need to purchase expensive drones, as well as convenience, as there is no need to manage maintenance and operation. The model also offers scalability to use more often or less often based on business needs and enables access to advanced drone technology sensors or attachments like spraying, without the need for specialized training.

Accurate land surveys are essential for the planning, designing, and executing of roads, bridges, and building projects for cities, commercial, and residential projects, and are required for legal purposes. Remotely piloted drones with an array of sensors and cameras, LiDAR (Light Detection and Ranging), and GPS systems for capturing high-resolution pictures and data are revolutionizing the land survey industry gathering aerial data across expansive terrains in a matter of hours instead of weeks or months using more traditional photogrammetry methods. Continued…Read this full release by visiting: https://www.financialnewsmedia.com/news-zena/

In Additional ZENA News: ZenaTech’s (NASDAQ:ZENA) Expands Domestic Manufacturing for US Commercial Customers and US Defense Without Needing to Increase Prices – ZenaTech, Inc. (“ZenaTech”), a technology company specializing in AI (Artificial Intelligence) drones, Drone as a Service (DaaS), enterprise SaaS and Quantum Computing solutions, today provides an update on its US-based ZenaDrone subsidiary’s expansion plans for “Made in America” manufacturing in light of the recent expanded tariffs announced by the current US Administration. ZenaTech maintains its commitment to domestic manufacturing for US defense drone solutions, including strategic local investments and military-compliant supply chains. ZenaDrone will now move some of its commercial drone production for US commercial customers to Arizona, meaning no need to increase prices for customers to offset tariff costs.

ZenaDrone’s headquarters is in Phoenix, Arizona, which includes sales, administration, research and development, and aerial testing operations. The company plans to expand its manufacturing capabilities over the next two months to produce drones for US commercial customers in addition to planned production for the US military. This expansion will include up to 2,000 additional square feet of production space. This will be the second global manufacturing facility; the company currently has development and production facilities for the ZenaDrone 1000 and IQ series of drones at its 10,000-square-foot facility in Sharjah, UAE.

In response to the evolving trade landscape, ZenaTech also expects that the expansion of its Phoenix-based manufacturing facility will bring over 150 new jobs to the region by the end of 2026.

“While tariffs can be challenging, they also reveal which companies are truly agile. ZenaTech has always been long-term in our thinking; engaging in smart resource management and supply chains and prepared to navigate global shifts,” said CEO Shaun Passley, Ph.D. “With increased US bans on Chinese drones and components and local incentives for domestic production, we are well-positioned to expand our manufacturing in Arizona, also creating more high-quality American jobs,” added Mr. Passley.

Continued…

Read this full release by visiting:
https://www.zenatech.com/newsroom/

Other recent developments in the drone industry include:

Safe Pro Group Inc. (NASDAQ: SPAI), a leading innovator in AI-powered defense and security technologies, recently announced a service expansion for its Airborne Response drone services subsidiary. Under its existing multi-year agreement with one of Florida’s largest electric utilities, Airborne Response will now deliver enhanced drone-based critical infrastructure assessment services in addition to its routine monitoring and pre/post-hurricane recovery programs.

This new order builds on an established partnership and expands Airborne’s role beyond standard visual inspections and hurricane recovery efforts to advanced “Condition Assessment” (CA) services—a mission-critical capability for modern grid resilience. It is anticipated that future assessments could leverage proprietary AI imaging technology to proactively detect faults across transmission lines, substations, and pole infrastructure. As such, the Company intends to explore further support for high-value assessment work in the future utilizing in-house resources such as its Safe Pro AI unit and its patented artificial intelligence (AI)-powered imagery processing technology or through the formation of development partnerships with third-party solution vendors.

AgEagle Aerial Systems Inc. (NYSE: UAVS) a leading provider of best-in-class unmanned aerial systems (UAS), sensors and software solutions for customers worldwide in the commercial and government verticals, recently announced the appointment of Steve Mathias as Vice President of Global Sales and Business Development and Erik de Badts as Global Head of MicaSense Sales.

AgEagle CEO Bill Irby commented, “As we execute a multi-faceted strategic growth plan focused on expanding our global footprint, the addition of both Steve and Erik’s impressive pedigrees will drive innovation, foster collaboration, and ensure that we remain agile in an evolving UAS marketplace. Steve brings multi-decade expertise in military and commercial aviation, both crewed and uncrewed, while Erik is a true subject matter expert in multi-spectral sensing. We are confident their leadership will help strengthen key partner relationships, unlock new opportunities, and accelerate revenue growth.”

Ondas Holdings Inc. (NASDAQ:ONDS), a leading provider of private industrial wireless networks and commercial drone and automated data solutions through its Ondas Networks and Ondas Autonomous Systems (OAS) business units, reported financial and operating results for the fourth quarter and full year ended December 31, 2024.

“Ondas entered 2024 with deepening customer engagement and a growing business pipeline at OAS, allowing us to end the year with $10 million in backlog at OAS. We believe 2025 will be a record year with OAS expected to contribute at least $20 million in revenues of the expected Ondas Holdings revenue of $25 million,” said Eric Brock, Chairman and CEO of Ondas Holdings. “Our momentum in 2024 was supported by securing two key programs with a major military customer for our Optimus and Iron Drone platforms, opening the large and fast-growing global defense markets. Additionally, we fortified our financial position by securing $35 million of capital in the fourth quarter, supporting our strong growth outlook.

Avionics specialist Aerium recently launched a compact carrier board for the NVIDIA Jetson family of computers-on-modules (COMs), designed for being installed on-board drones to deliver in-flight machine learning and artificial intelligence (ML and AI) capabilities: the Lumen.

“The Lumen carrier board serves as the ideal partner for unlocking the full potential of Jetson modules, offering an array of features and functionalities tailored for diverse AI and edge computing applications,” claims Aerium of its creation. “The Lumen carrier board provides seamless compatibility and integration with NVIDIA Corporation (NASDAQ: NVDA) Jetson modules, delivering an optimal platform for developers, researchers, and enthusiasts to harness the power of AI at the edge.”

NVIDIA’s ever-growing Jetson family of computers-on-modules put the company’s in-house Arm-based processor cores, high-end graphics cores, and dedicated machine learning and artificial intelligence acceleration cores on a small board designed to drive everything from autonomous vehicles to advanced robotics — and when paired with a carrier like the Aerium Lumen, brought to our attention by CNX Software, drones.


About FN Media Group:

At FN Media Group, via our top-rated online news portal at www.financialnewsmedia.com, we are one of the very few select firms providing top tier one syndicated news distribution, targeted ticker tag press releases and stock market news coverage for today’s emerging companies. #tickertagpressreleases #pressreleases

Follow us on Facebook to receive the latest news updates:
https://www.facebook.com/financialnewsmedia

Follow us on Twitter for real time Market News:
https://twitter.com/FNMgroup

Follow us on Linkedin:
https://www.linkedin.com/in/financialnewsmedia/

DISCLAIMER: FN Media Group LLC (FNM), which owns and operates FinancialNewsMedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM has been compensated fifty one hundred dollars for news coverage of the current press releases issued by ZenaTech, Inc. by the Company. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information:

Media Contact email: [email protected] – +1(561)325-8757

SOURCE: FN Media Group



Posted on

NextNRG Reports Preliminary March 2025 Revenue Growth of 161% Year-Over-Year and Q1 Revenue Growth of 146%

Company Reports Third Consecutive Record Month

MIAMI, April 10, 2025 (GLOBE NEWSWIRE) — NextNRG, Inc. (Nasdaq: NXXT), a pioneer in AI-driven energy innovation—transforming how energy is produced, managed, and delivered through its advanced Utility Operating System, smart microgrid technology, wireless EV charging, and on-demand mobile fuel delivery solutions— today announced preliminary unaudited revenue and volume results for March 2025 and the first quarter of 2025. The company delivered its third consecutive record month, with March revenue increasing 161% year-over-year to approximately $6.15 million.

March 2025 Highlights

  • Revenue: $6,148,266 (vs. $2,354,048 in March 2024)
  • YoY Revenue Growth: 161%
  • Gallons Delivered: 1,799,955 (vs. 580,217 in March 2024)
  • YoY Gallon Growth: 210%

Q1 2025 Highlights

  • Revenue: $16,232,354 (vs. $6,597,119 in Q1 2024)
  • YoY Revenue Growth: 146%
  • Gallons Delivered: 4,688,045 (vs. 1,658,272 in Q1 2024)
  • YoY Gallon Growth: 183%

“We are pleased to report another record-breaking month as our growth trajectory continues to accelerate,” said Michael D. Farkas, Founder and CEO of NextNRG. “With volume nearly tripling year-over-year in March, our focus on disciplined expansion and operational execution is delivering measurable results. The successful integration of strategic acquisitions and our partnerships with major fleet operators are helping to validate our business model as we scale.”

Farkas continued, “With three consecutive months of all-time high performance, we are seeing strong market demand and consistent customer adoption of our mobile fueling platform. As we expand our AI-powered infrastructure and prepare for future deployments of smart microgrid and wireless charging technologies, we believe NextNRG is playing a key role in powering the transition to a cleaner, more flexible energy future.”

Note on Preliminary Results

These March and Q1 2025 financial results are preliminary and unaudited. Final figures may be subject to adjustment pending the completion of month-end and quarter-end closing procedures.

About NextNRG, Inc.

NextNRG, Inc. (NextNRG) is Powering What’s Next by implementing artificial intelligence (AI) and machine learning (ML) into renewable energy, next-generation energy infrastructure, battery storage, wireless electric vehicle (EV) charging and on-demand mobile fuel delivery to create an integrated ecosystem.

At the core of NextNRG’s strategy is its Utility Operating System, which leverages AI and ML to help make existing utilities’ energy management as efficient as possible; and the deployment of NextNRG smart microgrids, which utilize AI-driven energy management alongside solar power and battery storage to enhance energy efficiency, reduce costs and improve grid resiliency. These microgrids are designed to serve commercial properties, schools, hospitals, nursing homes, parking garages, rural and tribal lands, recreational facilities and government properties, expanding energy accessibility while supporting decarbonization initiatives.

NextNRG continues to expand its growing fleet of fuel delivery trucks and national footprint, including the acquisition of Yoshi Mobility’s fuel division and Shell Oil’s trucks, further solidifying its position as a leader in the on-demand fueling industry. NextNRG is also integrating sustainable energy solutions into its mobile fueling operations. The company hopes to be an integral part of assisting its fleet customers in their transition to EV, supporting more efficient fuel delivery while advancing clean energy adoption. The transition process is expected to include the deployment of NextNRG’s innovative wireless EV charging solutions.

To find out more visit: www.nextnrg.com

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statement describing NextNRG’s goals, expectations, financial or other projections, intentions, or beliefs is a forward-looking statement and should be considered an at-risk statement. Words such as “expect,” “intends,” “will,” and similar expressions are intended to identify forward-looking statements. Such statements are subject to certain risks and uncertainties, including, but not limited to, those related to NextNRG’s business and macroeconomic and geopolitical events. These and other risks are described in NextNRG’s filings with the Securities and Exchange Commission from time to time. NextNRG’s forward-looking statements involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although NextNRG’s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by NextNRG. Except as required by law, NextNRG undertakes no obligation to update any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements.

Investor Relations Contact

NextNRG, Inc.
Sharon Cohen
[email protected]



Posted on

Baxter Launches New Room Temperature Hemopatch Sealing Hemostat for Rapid and Convenient Application During Surgery

Baxter Launches New Room Temperature Hemopatch Sealing Hemostat for Rapid and Convenient Application During Surgery

  • Hemopatch Sealing Hemostat with room temperature storage now available in Europe
  • New product evolution enables direct accessibility in the operating room
  • Innovation is a direct result of collaborative efforts with surgeons, helping to ensure that customer needs are met and promoting enhanced patient care

VIENNA–(BUSINESS WIRE)–
Baxter International Inc. (NYSE:BAX), a global leader in advancing surgical innovation, today announced the introduction of Hemopatch Sealing Hemostat with room temperature storage at a symposium in Austria. The evolution of the product optimizes accessibility in the operating room, delivering an immediate solution for surgeons to control bleeding or prevent leakage. The product is now available to order throughout Europe.

“For over a decade, Hemopatch Sealing Hemostat has offered surgeons a reliable solution for tissue sealing, dura sealing, and hemostasis,” said Steve Wallace, president, Advanced Surgery at Baxter. “The product evolution to include room temperature storage is a result of close collaboration between surgeons and Baxter. Removing the need for refrigeration addresses the needs of our customers to have the product on hand in critical situations. We are proud to continue Baxter’s legacy of innovation in sealing and hemostasis.”

HemopatchSealing Hemostat is a ready-to-use absorbable collagen pad intended for tissue sealing, dura sealing and hemostasis, and is effective and safe to use in open surgery and minimally invasive surgery. In a registry of real-world data across Europe, the product has been shown to achieve rapid and sustainable hemostasis in many surgical specialties.1

General Surgeon, Prof. Dr. med. Selman Uranüs said, “More than 10 years ago, I first used Hemopatch Sealing Hemostat for experimental testing. Since then, I have been using it in my daily practice because of its unique characteristics as a sealing hemostatic patch, especially in laparoscopic surgery. In my opinion, eliminating the need for refrigeration and increasing product shelf life are crucial improvements because it enables surgeons to have the product available in the operating room when it matters most. After application, the product shows an enhanced adhesive strength supporting us surgeons to achieve better surgical outcomes.”2

For more information on Hemopatch Sealing Hemostat with room temperature storage, visit https://advancedsurgery.baxter.eu/hemopatch

About Hemopatch Sealing Hemostat

Hemopatch Sealing Hemostat consists of a soft, thin, pliable, flexible pad of collagen derived from bovine dermis, coated with NHS-PEG (pentaerythritol polyethylene glycol ether tetra-succinimidyl glutarate). Due to its flexible structure, the application of Hemopatch Sealing Hemostat to the site where hemostasis / sealing is desired is easily controlled. For differentiation, the non-coated side is marked with blue squares using a biocompatible colorant.3

About Baxter

Every day, millions of patients, caregivers and healthcare providers rely on Baxter’s leading portfolio of diagnostic, critical care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years, we’ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers who make it happen. With products, digital health solutions and therapies available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit www.baxter.com and follow us on X, LinkedIn and Facebook.

INDICATIONS

Hemopatch Sealing Hemostat is indicated as a hemostatic device and surgical sealant across various soft tissues (cardiovascular, connective tissue, parenchyma, serosa, viscera), and dura for procedures in which control of mild or moderate bleeding or leakage of other body fluids or air by conventional surgical techniques is either ineffective or impractical. Hemopatch Sealing Hemostat may be used to augment dura closure techniques to close small dural defects (≤3mm) following traumatic injury, excision, retraction or shrinkage of the dura mater.

IMPORTANT RISK INFORMATION

  • Hemopatch Sealing Hemostat is not recommended to be used in pulsatile, severe bleedings.
  • The use of Hemopatch Sealing Hemostat is not recommended in the presence of an active infection.
  • When used in, around, or in proximity to foramina in bone, areas of bony confine, the spinal cord, the brain and/or cranial nerves, care should be exercised to avoid overpacking as Hemopatch Sealing Hemostat may expand upon absorption of liquid, creating the potential for neural damage.
  • Hemopatch Sealing Hemostat is not intended as a substitute for meticulous surgical technique and the proper application of ligatures or other conventional procedures for hemostasis and sealing.
  • Do not compress Hemopatch Sealing Hemostat into blood vessels or use intravascularly.

Rx Only. For safe and proper use please refer to full device Instructions for Use for Contraindications, Warnings, and Precautions.

Forward-Looking Statements

This release includes forward-looking statements concerning potential benefits associated with Hemopatch Sealing Hemostat. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: demand for and market acceptance for new and existing products; product development risks; inability to create additional production capacity in a timely manner or the occurrence of other manufacturing or supply difficulties (including as a result of natural disasters, public health crises and epidemics/pandemics, regulatory actions or otherwise); satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; product quality, manufacturing or supply, or patient safety issues; changes in law and regulations; and other risks identified in Baxter’s most recent filing on Form 10-K and Form 10-Q and other SEC filings, all of which are available on Baxter’s website. Baxter does not undertake to update its forward-looking statements.

Hemopatch Sealing Hemostat and Baxter are registered trademarks of Baxter International Inc.

____________________

1 Lombardo C, Lopez-Ben S, Boggi U, Gutowski P, Hrbac T, Krska L, Marquez-Rivas J, Russello D, York E, Zacharias M. Hemopatch® is effective and safe to use: real-world data from a prospective European registry study. Updates Surg. 2022 Oct;74(5):1521-1531. doi: 10.1007/s13304-022-01353-y. Epub 2022 Aug 20. PMID: 35986865; PMCID: PMC9481486.

2 Prof. Dr. med. Selman Uranüs, is one of the speakers at the symposium and has signed a speaker agreement

3 IFU Hemopatch Sealing Hemostat 09/2024

 

Media Contact

Peggy Dekker-Kühnen, (224) 948-5353

[email protected]

Investor Contact

Clare Trachtman, (224) 948-3020

KEYWORDS: Austria Europe

INDUSTRY KEYWORDS: Research Medical Devices Medical Supplies Other Health Managed Care Health General Health Other Science Science

MEDIA:

Logo
Logo
Posted on

Nuvve Partners with Jefferies to Power Infrastructure Financing for “Electrify New Mexico”

Nuvve Partners with Jefferies to Power Infrastructure Financing for “Electrify New Mexico”

SAN DIEGO–(BUSINESS WIRE)–Nuvve Holding Corp. (Nasdaq: NVVE), a global leader in grid modernization and vehicle-to-grid (V2G) technology, today announced it has selected Jefferies LLC, one of the world’s leading full-service investment banking and capital markets firms, as its exclusive infrastructure financing partner for the Electrify New Mexico initiative.

Jefferies will work with Nuvve to structure and secure capital markets transactions to fund the buildout of electric vehicle (EV) charging infrastructure, grid-integrated mobility hubs, and other clean energy assets tied to Nuvve’s landmark contract awarded by the State of New Mexico.

“Jefferies brings Electrify New Mexico closer to reality and offers a strong endorsement of both our vision and our leadership in grid modernization,” said Gregory Poilasne, CEO and Founder of Nuvve. “We’re not just planning for the future; we’re building it with key strategic partners committed to building this critical infrastructure.”

Jefferies brings deep expertise in energy infrastructure finance and has a global reputation for transformative clean energy projects in the U.S. Their global track record in financing clean energy projects positions them as an ideal partner to unlock scalable capital solutions for one of the most ambitious state electrification efforts in the U.S. Their involvement exhibits growing investor confidence in Nuvve’s business model and the long-term potential of the Electrify New Mexico initiative.

The announcement comes as New Mexico continues to demonstrate strong political movement to lead on electrification and grid innovation. During the most recent legislative session, nearly 100 bills were introduced that directly or indirectly support clean energy goals, including proposed investments in EV infrastructure, grid resilience, and zero-emission transportation. This reflects a clear commitment to building a more sustainable energy future.

“We’re executing on a bold and necessary transformation,” said Ted Smith, CEO of Nuvve New Mexico LLC. “With partners like Jefferies and strong momentum at the state level, we’re building a coalition capable of making New Mexico a national leader in grid innovation and clean energy deployment.”

To support the project’s success, Nuvve formed Nuvve New Mexico LLC, a regional subsidiary dedicated to executing the statewide contract and spearheading local implementation.

About Nuvve

Founded in 2010, Nuvve Holding Corp. (Nasdaq: NVVE) has successfully deployed vehicle-to-grid (V2G) on five continents, offering turnkey electrification solutions for fleets of all types. Nuvve combines the world’s most advanced V2G technology and an ecosystem of electrification partners, delivering new value to electric vehicle (EV) owners, accelerating the adoption of EVs, and supporting a global transition to clean energy. Nuvve is making the grid more resilient, transforming EVs into mobile energy storage assets, enhancing sustainable transportation, and supporting energy equity in an electrified world. Nuvve is headquartered in San Diego, Calif., and can be found online at nuvve.com.

Media Contact For Nuvve:

Wes Robinson

[email protected]

(626) 201-2928

KEYWORDS: United States North America California New Mexico

INDUSTRY KEYWORDS: Public Policy/Government State/Local Automotive Utilities EV/Electric Vehicles Alternative Energy Energy

MEDIA:

Logo
Logo
Posted on

Worthington Steel Earns John Deere’s Highest Supplier Rating for 13th Consecutive Year

Worthington Steel Earns John Deere’s Highest Supplier Rating for 13th Consecutive Year

COLUMBUS, Ohio–(BUSINESS WIRE)–
Worthington Steel, Inc. (NYSE: WS) today announced it has once again been recognized as a Partner-level supplier in the John Deere Achieving Excellence Program, marking 13 consecutive years of receiving this honor. Partner-level status is Deere & Company’s highest supplier rating, awarded to companies that demonstrate exceptional quality, service and a commitment to continuous improvement.

“Our 13-year streak as a Partner-level supplier reflects the strength and dedication of our team,” said Geoff Gilmore, president and CEO of Worthington Steel. “We take great pride in delivering innovative steel solutions that help drive John Deere’s success, and we remain focused on raising the bar even higher.”

Members of Worthington Steel’s dedicated John Deere account team will accept the award at John Deere’s annual award ceremony in East Moline, Ill., this morning.

Worthington Steel supplies hot-rolled and cold-rolled cut-to-length steel sheets to John Deere Harvester Works in East Moline, Ill., John Deere Ottumwa Works in Ottumwa, Iowa and John Deere Horicon Works in Horicon, Wis., supporting the production of combine harvesters, hay and forage equipment and utility vehicles.

John Deere’s Achieving Excellence Program evaluates suppliers annually across multiple performance categories, including quality, delivery, process alignment, relationship and value creation. Worthington Steel’s long history of recognition includes John Deere Supplier of the Year awards in 2007 and 2015, a Supplier Innovation award in 2015 and Hall of Fame status in 2016 and 2021 for attaining back-to-back Partner-level ratings for five consecutive years.

About Worthington Steel

Worthington Steel (NYSE:WS) is a metals processor that partners with customers to deliver highly technical and customized solutions. Worthington Steel’s expertise in carbon flat-roll steel processing, electrical steel laminations and tailor welded solutions are driving steel toward a more sustainable future.

As one of the most trusted metals processors in North America, Worthington Steel and its approximately 5,000 employees harness the power of steel to advance our customers’ visions through value-added processing capabilities including galvanizing, pickling, configured blanking, specialty cold reduction, lightweighting and electrical lamination. Headquartered in Columbus, Ohio, Worthington Steel operates 32 facilities in seven states and six countries. Following a people-first Philosophy, commitment to sustainability and proven business system, Worthington Steel’s purpose is to generate positive returns by providing trusted and innovative solutions for customers, creating opportunities for employees and strengthening its communities.

Safe Harbor Statement

Worthington Steel wishes to take advantage of the Safe Harbor provisions included in the Private Securities Litigation Reform Act of 1995 (the “Act”). Statements by Worthington Steel which are not historical information constitute “forward looking statements” within the meaning of the Act. All forward-looking statements are subject to risks and uncertainties which could cause actual results to differ from those projected. Factors that could cause actual results to differ materially include risks, uncertainties and impacts described from time to time in Worthington Steel’s filings with the Securities and Exchange Commission.

Melissa Dykstra

Vice President

Corporate Communications and Investor Relations

Phone: 614-840-4144

[email protected]

KEYWORDS: United States North America Ohio

INDUSTRY KEYWORDS: Automotive Manufacturing Alternative Energy Manufacturing Energy Steel

MEDIA:

Logo
Logo
Posted on

Terreno Realty Corporation Acquires Property in Redmond, WA for $9.3 Million

Terreno Realty Corporation Acquires Property in Redmond, WA for $9.3 Million

BELLEVUE, Wash.–(BUSINESS WIRE)–Terreno Realty Corporation (NYSE:TRNO), an acquirer, owner and operator of industrial real estate in six major coastal U.S. markets, acquired an industrial property located in Redmond, Washington on April 9, 2025 for a purchase price of approximately $9.3 million.

The property consists of one industrial distribution building containing approximately 33,000 square feet on 1.5 acres. The property is at 9660 153rd Avenue NE on Seattle’s Eastside, provides two dock-high and one grade-level loading positions and parking for 30 cars. The property is 100% leased on a short-term basis. After the existing tenant vacates, the property will be renovated to contain approximately 26,000 square feet. The estimated stabilized cap rate after renovation is 5.5%.

Estimated stabilized cap rates are calculated as annualized cash basis net operating income stabilized to market occupancy (generally 95%) divided by total acquisition cost. Total acquisition cost includes the initial purchase price, the effects of marking assumed debt to market, buyer’s due diligence and closing costs, estimated near-term capital expenditures and leasing costs necessary to achieve stabilization.

Terreno Realty Corporation acquires, owns and operates industrial real estate in six major coastal U.S. markets: New York City/Northern New Jersey, Los Angeles, Miami, San Francisco Bay Area, Seattle and Washington, D.C.

Additional information about Terreno Realty Corporation is available on the company’s web site at www.terreno.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws. We caution investors that forward-looking statements are based on management’s beliefs and on assumptions made by, and information currently available to, management. When used, the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “project,” “result,” “should,” “will,” “seek,” “target,” “see,” “likely,” “position,” “opportunity,” “outlook,” “potential,” “enthusiastic,” “future” and similar expressions which do not relate solely to historical matters are intended to identify forward-looking statements. These statements are subject to risks, uncertainties, and assumptions and are not guarantees of future performance, which may be affected by known and unknown risks, trends, uncertainties, and factors that are beyond our control, including risks related to our ability to meet our estimated forecasts related to stabilized cap rates, and those risk factors contained in our Annual Report on Form 10-K for the year ended December 31, 2024 and our other public filings. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, estimated, or projected. We expressly disclaim any responsibility to update our forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Accordingly, investors should use caution in relying on past forward-looking statements, which are based on results and trends at the time they are made, to anticipate future results or trends.

Jaime Cannon

415-655-4580

KEYWORDS: United States North America Washington

INDUSTRY KEYWORDS: Commercial Building & Real Estate Construction & Property REIT

MEDIA:

Logo
Logo
Posted on

BofA Launches ‘Golf with Us’ to Bring Affordable Rounds to More Than 50,000 Youth Nationwide

PR Newswire

Young players can enjoy rounds for $5 or less and instructional opportunities through partnership with Youth on Course


CHARLOTTE, N.C. and MONTEREY, Calif., April 10, 2025/PRNewswire/ — Bank of America today announced the launch of Golf with Us, a new initiative designed to grow the next generation of golfers.

Golf with Us offers youth, ages 6-18, a free one-year membership to Youth on Course, courtesy of Bank of America. Enrollment in the program is open until May 24, 2025, and includes access to thousands of courses in 97 markets for $5 or less per round. The courses are in the Youth on Course network.

“When kids get involved in sports, they learn first-hand about achieving their goals and develop lifelong skills that help them thrive,” said David Tyrie, President, Marketing, Digital & Specialized Consumer Client Solutions, Bank of America. “By working with Youth on Course to help make golf more accessible, we’re helping grow the sport while also making a positive impact in our communities.”

Through Golf with Us, BofA will also bring unique instructional opportunities to youth in select markets throughout the spring, summer and fall by hosting a series of free clinics featuring professional golfers, athletes and celebrities with a passion for golf.

Program membership also includes a registered handicap index in the United States Golf Association’s Golf Handicap Information Network (GHIN) system, continued development as well as learning opportunities. Interested families can enroll in Youth on Course and learn more about the Golf with Us offer at BofA.com/GolfwithUs.

“Golf has the power to shape young lives in incredible ways – not just through the sport itself, but through the friendships, confidence and opportunities it creates,” said Youth on Course CEO Adam Heieck. “Through this partnership with Bank of America, we’re making it possible for more kids across the country to step onto the course and discover what’s possible. This partnership is about more than just golf; it’s about opening doors and changing futures.”

Youth on Course and BofA recently announced a multi-year, strategic partnership to expand golf access across the country for young players who are challenged to find an affordable place to play. As part of the agreement, BofA is helping fund widespread expansion of municipal course locations participating in the program. To date, more than 2,000 courses are Youth on Course partners nationwide.

The bank will promote Golf with Us through a series of commercials beginning during the Masters Tournament. BofA serves as Champion Partner of the Masters Tournament and has partnered with the Augusta National Women’s Amateur since 2019, hosting annual golf clinics for youth in the Augusta, GA area. In 2025, BofA became the presenting partner of the More Than Golf Invitational for female amateur golfers in partnership with the ANNIKA Foundation founded by golfing legend Annika Sorenstam. In addition, BofA has partnered since 2002 with the Latin America Amateur Championship and Asia-Pacific Amateur Championships.

Beyond its growing golf partnership portfolio, BofA also partners with iconic brands in sports that share a vision for excellence and achievement to deepen client relationships, inspire and showcase teammates, create lasting economic impact in communities, and drive growth, globally and locally, through the power of sport. To learn more, visit about.bankofamerica.com/en/making-an-impact/sports 

Bank of America
Bank of America is one of the world’s leading financial institutions, serving individual consumers, small and middle-market businesses and large corporations with a full range of banking, investing, asset management and other financial and risk management products and services. The company provides unmatched convenience in the United States, serving approximately 69 million consumer and small business clients with 3,700 retail financial centers, approximately 15,000 ATMs (automated teller machines) and award-winning digital banking with approximately 58 million verified digital users. Bank of America is a global leader in wealth management, corporate and investment banking and trading across a broad range of asset classes, serving corporations, governments, institutions and individuals around the world. Bank of America offers industry-leading support to approximately 4 million small business households through a suite of innovative, easy-to-use online products and services. The company serves clients through operations across the United States, its territories and more than 35 countries. Bank of America Corporation stock is listed on the New York Stock Exchange (NYSE: BAC).

Youth on Course


Youth on Course
, a 501(c)3 nonprofit organization headquartered in Monterey, Calif., provides youth 18 and under access to life-changing opportunities through golf. Since its inception in 2006, Youth on Course members have played more than 4 million subsidized rounds of golf for $5 or less at thousands of partner courses throughout the United States, Canada, and Australia. Its members include the top juniors in the sport, competing on the AJGA and Underrated Tours, the inaugural United States Golf Association U.S. National Development Team, and all collegiate levels. The organization forges new pathways for youth to grow in the game via opportunities including the DRIVE Club, Careers on Course, Leadership Council, and its annual College Scholarship awards. The Youth on Course Alumni Network extends membership to those 19 and older, offering opportunities for young adults to connect at complementary events, access exclusive deals, and network with the top employers in the golf industry. Supporters can participate in various initiatives including the Youth on Course 100 Hole Hike, Vintage Cup and Online Auction to help fund golf access for youth. More information about Youth on Course can be found by visiting youthoncourse.org or Facebook, Instagram, LinkedIn, TikTok and X.

Reporters may contact:

Andy Aldridge, Bank of America
Phone: 1.980.387.0514
[email protected]

Daniel Monroe, Youth on Course
Buffalo Groupe
Phone: 843.422.0682
[email protected]

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/bofa-launches-golf-with-us-to-bring-affordable-rounds-to-more-than-50-000-youth-nationwide-302425385.html

SOURCE Bank of America Corporation

Posted on

Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros’ Proprietary OncotoX-AML Clinical Program

Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros’ Proprietary OncotoX-AML Clinical Program

– The Steering Committee brings together distinguished clinical experts in AML from leading National Comprehensive Cancer Network Centers –

SEATTLE–(BUSINESS WIRE)–
Omeros Corporation (Nasdaq: OMER) today announced the establishment of the Omeros Oncology Clinical Steering Committee to advance Omeros’ OncotoX biologics program focused on acute myeloid leukemia (AML). AML is the most fatal form of leukemia and accounts for approximately 80 percent of acute leukemias in adults and one-third of all cancers affecting the blood/bone marrow, representing a high unmet need. Omeros’ OncotoX program for AML consists of proprietary targeted, engineered molecules (about half the size of an antibody) that deliver a toxic payload within the cancer cells, thereby killing them.

Members of the Omeros Oncology Clinical Steering Committee include:

  • Naval Daver, M.D., Professor and Director of the Leukemia Research Alliance Program in the Department of Leukemia at MD Anderson Cancer Center (Chair of the Omeros Oncology Clinical Steering Committee)
  • Aref Al-Kali, M.D., Chair of the Acute Myeloid Group and Research Chair of the Acute Leukemia and Myeloid Neoplasms Disease Group at Mayo Clinic
  • Jessica K. Altman, M.D., Professor of Medicine in the Division of Hematology and Oncology and Director of the Leukemia Program of Robert H. Lurie Comprehensive Cancer Center at Northwestern University
  • Jayastu Senapati, M.B.B.S., M.D., D.M., Assistant Professor in the Department of Leukemia at MD Anderson Cancer Center
  • Mithun Shah, M.D., Ph.D., Assistant Professor of Medicine and Oncology, and Consultant in the Division of Hematology at Mayo Clinic
  • Anthony S. Stein, M.D., Co-director of the Gehr Family Center for Leukemia Research within the Hematologic Malignancies and Stem Cell Transplantation Institute at City of Hope
  • Eytan M. Stein, M.D., Chief of the Leukemia Service and Director of the Program for Drug Development in Leukemia in the Division of Hematologic Malignancies at Memorial Sloan Kettering Cancer Center
  • Roland B. Walter, M.D., Ph.D., M.S., Professor in the Translational Science and Therapeutics Division and José Carreras/E. Donnall Thomas Endowed Chair for Cancer Research at the Fred Hutchinson Cancer Center

The steering committee will, among other activities, assist Omeros with development of the OncotoX-AML program, clinical trial design and interactions with institutional review boards and will participate in OncotoX-AML clinical trials.

“AML is a devastating disease, and these patients have difficulty tolerating the side effects of chemotherapeutic agents and current antibody-drug conjugates, which generally have a narrow therapeutic index,” stated Naval Daver, M.D., Professor and Director of the Leukemia Research Alliance Program in the Department of Leukemia at MD Anderson Cancer Center and Chair of the Omeros Oncology Clinical Steering Committee. “The OncotoX platform is designed to kill only dividing cancer cells while sparing normal cells. In animal models using cell lines derived from AML patients, the OncotoX-AML molecule has shown superior efficacy to current standard of care in AML treatment, and its potential utility extends broadly beyond AML to other types of leukemia. Together with my esteemed physician-scientist colleagues on the steering committee, I look forward to advancing the Omeros therapeutic for AML and bringing this novel treatment to patients as quickly as possible.”

Across extensive in vivo and ex vivo studies, the OncotoX-AML therapeutic has shown to be highly effective even at very low doses, providing a significant survival benefit over currently approved combination therapy (venetoclax and azacytidine). These studies, conducted with human cell lines in well-established animal models and considered predictive of clinical response, have targeted AML tumors with mutational backgrounds commonly found in nearly 90 percent of AML patients (TP53, NPM1, KMT2a, and FLT3) indicating that the OncotoX-AML therapeutic could be “mutation-agnostic,” a currently large unmet need for oncologists and their patients. In studies using primary AML derived from patients, the OncotoX molecule preferentially and efficiently kills AML blasts (abnormal myeloid cells). OncotoX-AML also targets leukemia stem cells (LSC), which are often refractory to chemotherapy and represent another major challenge in the treatment of AML. The OncotoX-AML therapeutic is designed specifically to kill both AML blasts and LSCs that can lead to relapse. Preliminary in vivo tolerability studies demonstrate that the OncotoX therapeutic is well tolerated at doses substantially greater than one order of magnitude above efficacious doses without causing neutropenia or meaningful changes in blood chemistry values.

Omeros is initiating IND-enabling work for its OncotoX-AML therapeutic. Clinical efficacy in AML, considered one of the most aggressive leukemias, is thought to bode well for a therapeutic agent’s broad applicability across leukemias. In addition to OncotoX-AML, Omeros’ portfolio of oncology platforms include signaling and antigen-driven immunomodulators, immune memory-enhancing immunostimulators, and an adoptive T-cell technology that, unlike other cell therapy approaches, does not require cellular engineering.

“We are very pleased to be working with all the members of our oncology steering committee,” said Gregory A. Demopulos, M.D., Omeros’ Chairman and Chief Executive Officer. “Each is an internationally recognized leader in the fields of leukemia and AML and has been integrally involved in the development of new treatments for their patients. Their willingness to invest time and effort in our OncotoX-AML program is a strong endorsement of our molecule’s potential and, with their help, we look forward to assessing this next-generation therapeutic in AML patients.”

In the U.S. alone, AML is diagnosed in over 20,000 patients annually and is responsible each year for more than 11,000 deaths. In 2030, the global AML therapeutic market size is projected to be over $6 billion with the leukemia therapeutic market forecast at $29 billion.

About Omeros’ Oncology Programs

Omeros’ oncology programs are informed by a deep understanding of both the innate (complement-mediated) and adaptive (CD4 & CD8 T-cells) immune systems to derive highly differentiated, first-in-class therapeutic programs to treat a wide range of cancers. While significant progress has been made within oncology through targeted therapies, advanced biologics and immuno-therapies, toxicity and efficacy shortcomings remain significant. Omeros is focused on moving beyond these approaches with a family of wholly novel molecular and cellular platforms designed to be more effective, targeting both cell-surface and intracellular cancer antigens, with less toxicity. Our oncology franchise involves three distinct platforms – OncotoX, immunomodulators, and immunostimulators in combination with adoptive T-cell therapy. IND-enabling work has been initiated to advance to clinic our OncotoX-AML program comprised of engineered molecules designed to target and kill cancer cells with precision. Our immunomodulator platform is based on our identifying and evidencing the importance of certain molecules that selectively target T cells to regulate and potentiate immune responses. Our adoptive T-cell technology, unlike other cell therapy approaches, does not require cellular engineering and is being developed in concert with our immunostimulator platform to advance beyond the challenges of current vaccine approaches, which induce only transient and ineffective immune responses. By combining tumor antigens with a potent adjuvant, these novel, engineered biologics are designed specifically to target and activate antigen-presenting cells, leading to amplification of cancer-specific T and B cells to eliminate existing tumor cells and, importantly, to generate immune memory against future cancer relapse. Collectively, our portfolio of oncology platforms has the potential to deliver substantially more effective and safer treatments broadly across hematological malignancies and solid tumors.

About Omeros Corporation

Omeros is an innovative biopharmaceutical company committed to discovering, developing and commercializing first-in-class small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases and cancers, as well as addictive and compulsive disorders. Omeros’ lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Omeros’ long-acting MASP-2 inhibitor OMS1029 has successfully completed Phase 1 single- and multiple-ascending dose clinical studies. Zaltenibart, Omeros’ inhibitor of MASP-3, the key activator of the alternative pathway of complement, is in Phase 3 clinical development for paroxysmal nocturnal hemoglobinuria and is being evaluated in an ongoing Phase 2 clinical trial for complement 3 glomerulopathy. Funded by the National Institute on Drug Abuse, Omeros’ lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorder. Omeros also is advancing a broad portfolio of novel cellular and molecular immuno-oncology programs. For more information about Omeros and its programs, visit www.omeros.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are subject to the “safe harbor” created by those sections for such statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “likely,” “look forward to,” “may,” “objective,” “plan,” “potential,” “predict,” “project,” “should,” “slate,” “target,” “will,” “would” and similar expressions and variations thereof. Forward-looking statements, including statements regarding the anticipated safety and therapeutic benefits of Omeros’ drug candidates and plans for future development thereof are based on management’s beliefs and assumptions and on information available to management only as of the date of this press release. Omeros’ actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, our financial condition and results of operations, inability to raise capital when required to fund our operations and development plans, unfavorable, unexpected or inconclusive results of our preclinical and clinical development activities, unexpected outcomes of regulatory processes in relevant jurisdictions, including those associated with other Omeros’ development programs, challenges associated with manufacture or supply of our drug candidates or other materials needed to support preclinical and clinical development, intellectual property claims, competitive developments, litigation, and the risks, uncertainties and other factors described under the heading “Risk Factors” in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2025. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Jennifer Cook Williams

Cook Williams Communications, Inc.

Investor and Media Relations

[email protected]

KEYWORDS: United States North America Washington

INDUSTRY KEYWORDS: Stem Cells Biotechnology Health Pharmaceutical Oncology Health Technology Medical Devices Research Infectious Diseases Science Clinical Trials

MEDIA:

Logo
Logo
Posted on

Global Blue Releases the Monthly Tax Free Shopping Business Update for March 2025

Global Blue Releases the Monthly Tax Free Shopping Business Update for March 2025

  • Fresh data from Global Blue shows a softening in Tax Free Shopping growth across Continental Europe and Asia Pacific.
  • Globally, Issued Sales in Store (like-for-like year-on-year performance) reached +2%1 in March 2025, compared to +10% in February. This softening was influenced by less favourable exchange rates and the shift in the Ramadan calendar2.

SIGNY, Switzerland–(BUSINESS WIRE)–A stable performance in Continental Europe

In Continental Europe, the Issued Sales in Store increased by +7%1 in March compared to +9%1 in February 2025. This performance was driven by a +9%1 increase in the number of shoppers, as in February, while the average spend per shopper softened by -2%1, linked to a less favorable USD/EUR exchange rate.

Among key origin markets, US Tax Free Spend grew by a solid +16%¹ year-on-year, compared with +31% over the last three months3, a deceleration influenced by a less favorable USD/EUR exchange rate. Mainland Chinese shoppers Tax Free Spend recorded a slight rebound at +6%1 versus last year, compared to -4% over the last three months. Meanwhile, GCC shoppers’ Tax Free spend softened to -12%1 versus +21% in February, reflecting the ten-day shift of the beginning of Ramadan compared to 2024. This shift negatively impacted March 2025 figures and is expected to have a positive impact on April 2025 figures.

Across key destination markets, March saw a mixed performance: Spain led with +21%1, France and Italy at +6%1, while Germany was flat1.

A softened performance in Asia Pacific

In Asia Pacific, the Issued Sales in Store growth softened to -7%1 in March 2025, compared to February 2025 (+10%1). This softening was influenced by a less favorable Yen exchange rate and a high basis of comparison. Performance was shaped by a +7%1 increase in the number of shoppers, offset by a -13%1 decline in the average spend per shopper.

Among key origin markets, Tax Free Spend progression softened across most nationalities, impacted by a stronger Yen in Japan. Mainland Chinese Tax Free Spend eased to -1%1 compared to +19% in February. Hong Kong and Taiwan shoppers’ Tax Free Spend recorded a decline at -17% versus -11% in February, while North East Asia shoppers’ Tax Free Spend decreased by -42%1 versus -34% the previous month.

Regarding destination markets, March saw a strong performance in South Korea at +45%1. In contrast, Japan recorded a softening of -7%¹, impacted by less favorable exchange rates, while Singapore eased to -21%¹, impacted by a high basis of comparison.

Worldwide Year-on-Year Growth Rate (2025 vs. 2024)

Issued SIS L/L

Year-on-Year Growth

Destination

market weight in

Issued SIS 2024

 

March

2025

 

February

2025

 

January

2025

 

December

2024

 

CY

Q4 2024

 

CY

Q3 2024

France

 

16%

+6%

+7%

+15%

+19%

+13%

+2%

Italy

 

16%

+6%

+9%

+22%

+24%

+19%

+16%

Spain

 

11%

+21%

+16%

+28%

+22%

+21%

+24%

Germany

 

5%

+0%

+9%

+0%

+14%

+10%

+5%

Other countries

 

16%

+3%

+6%

+21%

+20%

+17%

+10%

Total Continental Europe

 

64%

+7%

+9%

+19%

+20%

+16%

+11%

Japan

 

26%

-7%

+14%

+56%

+32%

+33%

+57%

Singapore

 

6%

-21%

-12%

+8%

+6%

+10%

-3%

South Korea

 

3%

+45%

+50%

+72%

+64%

+50%

+42%

Total Asia Pacific

 

35%

-7%

+10%

+46%

+29%

+29%

+40%

Total Latin America

 

1%

+38%

+50%

+53%

+32%

+33%

+23%

Total worldwide

 

100%

+2%

+10%

+29%

+23%

+21%

+19%

Worldwide Recovery Rate (versus 2019)

Issued SIS L/L

recovery

(in % of 2019)

Destination

market weight in

Issued SIS 2019

 

March

2025

 

February

2025

 

January

2025

 

December

2024

 

CY

Q4 2024

 

CY

Q3 2024

France

 

16%

171%

188%

190%

173%

159%

144%

Italy

 

17%

142%

141%

135%

147%

146%

146%

Spain

 

10%

189%

159%

201%

180%

167%

161%

Germany

 

9%

70%

79%

68%

86%

78%

75%

Other countries

 

19%

132%

151%

149%

140%

132%

126%

Total Continental Europe

 

71%

142%

148%

150%

147%

139%

133%

Japan

 

14%

219%

263%

364%

307%

299%

290%

Singapore

 

11%

89%

75%

99%

77%

83%

81%

South Korea

 

3%

192%

182%

230%

174%

169%

162%

Total Asia Pacific

 

28%

172%

178%

239%

196%

195%

186%

Total Latin America

 

1%

118%

127%

139%

132%

125%

104%

Total worldwide

 

100%

151%

158%

176%

163%

154%

145%

APPENDIX

GLOSSARY

– European Non-EU countries include: Shoppers who can reach destination by land transportation or less than a two hour flight. Ex: Swiss, British, Ukraine etc.

– Gulf Cooperation Council countries include: Kuwait, Qatar, Saudi Arabia, United Arab Emirates, Bahrain, Oman

– North East Asia countries includes: Japan, South Korea

– South East Asia countries includes: Indonesia, Thailand, Cambodia, Philippines, Vietnam, Malaysia, Singapore

ABOUT GLOBAL BLUE

Global Blue is the business partner for the shopping journey, providing technology and services to enhance the experience and drive performance.

With over 40 years of expertise, today we connect thousands of retailers, acquirers, and hotels with nearly 80 million consumers across 53 countries, in three industries: Tax Free Shopping, Payments and Post-Purchase solutions.

With over 2,000 employees, Global Blue generated €28bn Sales in Store and €422M revenue in FY 2023/24. Global Blue is listed on the New York Stock Exchange.

For more information, please visit www.globalblue.com

Global Blue Monthly Intelligence Briefing, March 2025, Source: Global Blue

1Growth rate variation year-on-year (2025 vs. the same period in 2024)

2Ramadan took place from March 10 to April 9 in 2024, and from February 28 to March 30 in 2025.

3Over the last three months: December 2024 – February 2025

MEDIA CONTACTS

Virginie Alem – Chief Marketing Officer and Chief Operating Officer Japan

Mail: [email protected]

KEYWORDS: Kuwait Southeast Asia Viet Nam Singapore Japan Italy Saudi Arabia United Arab Emirates Indonesia Bahrain Hong Kong Qatar Middle East Thailand Philippines Malaysia China Taiwan Oman Germany Asia Pacific Europe Cambodia France Spain South Korea

INDUSTRY KEYWORDS: Payments Online Retail Retail Technology Other Travel Transportation Travel

MEDIA:

Logo
Logo